NeuroProof

Executive Summary

NeuroProof is a German Contract Research Organization (CRO) founded in 2006, specializing in pre-clinical neuroscience drug discovery and neurotoxicity testing. The company leverages Microelectrode Array (MEA) technology combined with AI-driven analysis to conduct functional phenotypic screening using primary neuronal cultures and human iPSC-derived neurons. Its service portfolio includes disease model development, target validation, and compound profiling for central nervous system (CNS) disorders. By integrating advanced electrophysiology with machine learning, NeuroProof offers a differentiated platform that addresses the high failure rates in CNS drug development, providing clients with more predictive pre-clinical data. The company operates in Göttingen, Germany, and serves a growing demand for specialized CRO services in the neuroscience space.

Upcoming Catalysts (preview)

• Q4 2026Launch of expanded iPSC-derived neuron model panel for Alzheimer's and Parkinson's disease65% success
• Q3 2026Strategic partnership with a top-20 pharma for CNS drug screening services50% success
• H1 2027Release of an AI-powered neurotoxicity prediction platform as a standalone software product40% success